BURL FORGEY: Open Payments
NPI 1649336082 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$826 in 39 payments from 13 companies in 2025. Trend: 2023 $38 · 2024 $709 · 2025 $826
Food & beverage: $826
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $193 |
| Vanda Pharmaceuticals Inc. | 3 | $103 |
| Sage Therapeutics, LLC | 5 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Axsome Therapeutics, Inc. | 2 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Lundbeck LLC | 2 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $48 |
| Almatica Pharma LLC | 1 | $26 |
Products named: VRAYLAR, REXULTI, FANAPT, ZURZUVAE, CAPLYTA, Auvelity, AUSTEDO XR, Qelbree.
Industry payments across LA — which companies pay providers there.
